Added to YB: 2026-09-15
Pitch date: 2026-09-11
EPRX [neutral]
Eupraxia Pharmaceuticals Inc.
-3.86%
current return
Author Info
No bio for this author
Company Info
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Market Cap
CAD 555.4M
Pitch Price
CAD 11.66
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.96
P/E
-8.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference coverage day 4 session 1 - Eupraxia Pharmaceuticals Inc.
EPRX (quick overview): Eupraxia’s EP104 GI could replace twice-daily steroids for eosinophilic esophagitis with physician-administered, local drug release lasting approximately one year. Management reported ~80% clinical remission at six months in open-label Phase 2A; a placebo-controlled Phase 2B interim readout is expected in Q4. At $8.39, upside could be attractive if efficacy holds, but open-label evidence, reimbursement uncertainty and biologic competition are key risks.
Read full article (2 min)